《新股消息》威高血液淨化提交上市申請
威高集團旗下威高血液淨化向聯交所提交上市申請,聯席保薦人為花旗、華泰國際及華興資本。早前有外電消息指,威高血液淨化目標集資約5億美元。
公司主要提供全面血液淨化產品,包括透析器、透析機、血液管路等血液透析產品以及腹膜透析液等腹膜透析產品,目前共有219款自研血液透析產品。根據市場研究機構數據,公司2021年透析器銷售額市佔率為32.4%,血液管路銷售額市佔率32.6%,均位列內地市場第一位。
初步招股文件顯示,威高血液淨化去年度持續經營業務收入達29.47億元人民幣(下同),按年升14.9%,年內利潤則按年下跌12.6%至2.69億元。
威高血液淨化透露,計劃在港上市後的適當時間進行A股的發行及上市,並已就A股發行提交上市前輔導的備案,有關申請已於2020年12月獲中國證監會山東監管局受理,目前尚未確定擬發售的A股的規模及範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.